Hibsago (bepirovirsen) approved in the US for the treatment of chronic hepatitis B (CHB)
GSK's Hibsago (bepirovirsen) approved in the US for chronic hepatitis B (CHB) treatment. Phase III trials showed 19% functional cure rate, significantly higher than standard care. CHB affects 1.7 million in the US. GSK plans further regulatory submissions.
How this was made
The 30-second read
Why it matters
The approval adds a novel therapy to GSK's portfolio, addressing an unmet need and offering a functional cure for a subset of patients.
Market read
Regulatory approval of a novel HBV therapy is a material event for GSK and could influence the pharma sector's outlook on antisense drugs.
What to watch
Potential safety concerns (hepatic flares, thrombocytopenia) may temper investor enthusiasm.
Background
GSK announced FDA approval of Hibsago, a first‑in‑class antisense oligonucleotide, for chronic hepatitis B in combination with nucleos(t)ide analog therapy.
Ticker impact
FDA approval of Hibsago (bepirovirsen) for chronic hepatitis B provides a new therapeutic option and potential revenue stream for GSK.
upward pressure as investors price in future sales and market share gains.
First‑time US approval of a first‑in‑class antisense drug, backed by Phase III data showing 19% functional cure, is material for a large‑cap pharma.
Market effects
May boost the broader hepatitis‑B treatment market and increase interest in antisense therapeutics.
US hepatitis‑B patient population (~1.7 million) could see new treatment options, potentially increasing US pharma sales.
GSK's global presence means the approval could influence worldwide HBV drug competition.
Counterpoint
If pricing is high or reimbursement is limited, the market impact could be muted.
Key entities
- CompanyGSK plc
Global pharmaceutical company receiving FDA approval.
- Regulatory AgencyFDA
U.S. regulator granting approval.
- CompanyIonis Pharmaceuticals
Licensor of bepirovirsen technology.
